Quenan S, Laffitte E
Service de dermatologie, hôpitaux universitaires de Genève (HUG), 1211 Genève, Suisse.
Service de dermatologie, hôpitaux universitaires de Genève (HUG), 1211 Genève, Suisse.
Ann Dermatol Venereol. 2018 Jan;145(1):50-59. doi: 10.1016/j.annder.2017.11.013. Epub 2017 Dec 28.
Pityriasis rubra pilaris is a rare heterogeneous dermatosis associating three clinical signs to different degrees: follicular corneal papules, reddish-orange palmoplantar keratoderma and erythematosquamous lesions that may in some cases be very extensive, interspersed with patches of healthy skin. The aetiology is unclear, and in most cases, the trigger factors consist of trauma or infection, probably in subjects with an existing predisposition. In other cases, the condition is associated with immunological disorders or, in familial cases, genetic keratinisation abnormalities similar to ichthyosis. Given the widely varying signs, several classifications have been proposed, based on clinical criteria and outcomes. The outcome varies in accordance with the clinical forms involved. Therapeutic approaches are poorly qualified and there have been no clinical trials due to the rarity of the disease. However, the best results appear to have been obtained using oral retinoids, with second-line therapy comprising methotrexate and cyclosporine. The landscape of therapeutic strategy seems to be changing with the advent of new anti-tumour necrosis factor and anti-interleukin-12/23 antibodies.
红皮病型毛发红糠疹是一种罕见的异质性皮肤病,不同程度地伴有三种临床体征:毛囊性角质丘疹、红橙色掌跖角化病和红斑鳞屑性皮损,在某些情况下皮损范围可能非常广泛,其间夹杂着健康皮肤斑块。病因尚不清楚,在大多数情况下,诱发因素包括创伤或感染,可能发生在已有易患倾向的个体中。在其他情况下,该病与免疫紊乱有关,或在家族性病例中,与类似于鱼鳞病的遗传性角化异常有关。鉴于体征差异很大,基于临床标准和结果已提出了几种分类方法。预后因所涉及的临床类型而异。治疗方法缺乏充分的验证,由于该病罕见,尚无临床试验。然而,使用口服维甲酸似乎取得了最佳效果,二线治疗包括甲氨蝶呤和环孢素。随着新型抗肿瘤坏死因子和抗白细胞介素-12/23抗体的出现,治疗策略的格局似乎正在发生变化。